DigestRedComo funciona
Red
/
Empresas
Br
No verificado

Bristol Myers Squibb

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

115 Comunicados de prensa

Ver todos los comunicados de prensa
20/01/2026
Técnica
Tecnología
Medicina - Varios
Biotecnología
Farmacéutica
Salud
Tecnología de la información
Oncología
Mercado laboral
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
12/01/2026
Ciencia
Material médico sanitario
Higiene alimentaria
Cardiología
Biotecnología
Salud
Farmacéutica
Industria
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
02/01/2026
Eventos
Web y redes sociales
Biotecnología
Salud
Ciencia
Farmacéutica
Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
19/12/2025
Mercado laboral
Industria
Política Nacional
Salud
Farmacéutica
Biotecnología
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
18/12/2025
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Biotecnología
Salud
Ciencia
Farmacéutica
Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
11/12/2025
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
10/12/2025
Acciones y Obligaciones
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Medicina - Varios
Bristol Myers Squibb Announces Dividend Increase
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
08/12/2025
Eventos
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
05/12/2025
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
03/12/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0